Tag Archives: NAVB

Navidea (NAVB) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Navidea (NAVB – Research Report) yesterday and set a price target of $7.00. The company’s shares closed last Friday at $3.27. According to TipRanks.com, McCarthy is a 5-star analyst with

Maxim Group Assigns a Buy Rating on Navidea (NAVB)

Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price target of $4.00. The company’s shares closed last Friday at $2.43. According to TipRanks.com, McCarthy is a 5-star analyst with

Maxim Group Releases a Buy Rating on Navidea (NAVB)

Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.10. According to TipRanks.com, McCarthy is a 4-star analyst with

Analysts Offer Insights on Healthcare Companies: Navidea (NYSE MKT: NAVB), Fennec Pharmaceuticals (NASDAQ: FENC) and CareDx (NASDAQ: CDNA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Navidea (NAVB – Research Report), Fennec Pharmaceuticals (FENC – Research Report) and CareDx (CDNA – Research Report) with bullish sentiments. Navidea (NAVB)

Navidea (NAVB) Gets a Buy Rating from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Navidea (NAVB – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $0.87. According to TipRanks.com, Bernardino is a

Maxim Group Maintains Their Buy Rating on Navidea (NAVB)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Navidea (NAVB – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $0.80. According to TipRanks.com, McCarthy has 0